Welcome to our dedicated page for Aerie Pharmaceut news (Ticker: AERI), a resource for investors and traders seeking the latest updates and insights on Aerie Pharmaceut stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aerie Pharmaceut's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aerie Pharmaceut's position in the market.
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) will participate in the virtual ARVO Annual Meeting from May 1-7, 2021, showcasing poster presentations on its research in glaucoma and ocular diseases. Key presentations include studies on netarsudil's effects in various contexts. Aerie will also present sponsored research on a new corticosteroid class aimed at reducing inflammation and lowering intraocular pressure (IOP). Chief Scientific Officer Casey Kopczynski will lead a Mini-Symposium discussing Rho Kinase inhibitors.
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) announced that Roclanda® (latanoprost + netarsudil) received marketing authorization from the MHRA in Great Britain for treating elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. This follows its European Commission authorization in January 2021. Roclanda® is notable for being the only fixed-dose combination eye drop therapy that doesn't contain a beta blocker. The company is exploring collaboration opportunities in Europe, viewing this as a vital regulatory milestone.
Aerie Pharmaceuticals (NASDAQ: AERI) announced that Vicente Anido, Jr., Ph.D., CEO, will present at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 12:45 p.m. ET. The presentation will provide an overview and business update of Aerie. A live webcast will be available on Aerie's website, with replays accessible for 10 business days. Aerie focuses on developing innovative therapies for open-angle glaucoma and other ocular diseases, with products like Rhopressa® and Rocklatan® aimed at reducing intraocular pressure.
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has published a peer-reviewed study in eLife demonstrating the potential of its glaucoma drug, Rhopressa® (netarsudil), to reverse tissue stiffness linked to steroid-induced ocular hypertension. This groundbreaking research indicates that Rhopressa® can significantly reduce intraocular pressure (IOP) by an average of 7-8 mmHg when used in patients unresponsive to other medications. The paper highlights the innovative role of netarsudil in treating glaucoma, affecting the trabecular meshwork and promoting healthier IOP regulation.
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) announces that David A. Hollander, M.D., M.B.A., presented on AR-15512, its dry eye product candidate, at the Ophthalmology Innovation Summit Dry Eye Innovation Showcase. The presentation included details on the Phase 2a study and the role of TRPM8 as a target for dry eye treatment. Aerie focuses on developing first-in-class therapies for open-angle glaucoma and other ocular diseases, with products like Rhopressa and Rocklatan already launched in the U.S.
Aerie Pharmaceuticals (NASDAQ: AERI) announced that CFO Richard J. Rubino will present at the Oppenheimer 31st Annual Virtual Healthcare Conference on March 17, 2021, at 8:00 a.m. ET. The presentation will offer an overview and business update for Aerie. Investors can access a live webcast on Aerie’s website, with a replay available for 10 business days. Aerie is focused on innovating ophthalmic therapies for open-angle glaucoma and ocular surface diseases. Its products include Rhopressa® and Rocklatan®, both aimed at reducing elevated intraocular pressure.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) reported Q4 2020 net revenues of $24.7 million, a nearly 23% increase from Q3, driven by strong sales in its glaucoma franchise. The company ended 2020 with over $240 million in cash. Although there’s no full-year 2021 guidance due to pandemic uncertainties, Aerie remains optimistic about reaching current analyst estimates. The firm has initiated a Phase 3 trial for Rhopressa® in Japan and is advancing its pipeline, including a new preclinical implant for wet AMD. The Q4 net loss narrowed to $46.1 million, or $1.00 per share.
Aerie Pharmaceuticals (NASDAQ: AERI) announced its participation in upcoming virtual investor conferences, highlighting its focus on ophthalmic therapies. Key events include the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, and the 41st Annual Cowen Healthcare Conference on March 2, 2021. CFO Richard J. Rubino and CEO Vicente Anido, Jr., Ph.D. will present at these forums. Live webcasts will be available on Aerie’s website, with replays accessible for 10 business days post-event. Aerie's products, Rhopressa® and Rocklatan®, aim to treat elevated intraocular pressure in glaucoma patients.
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) will release its fourth quarter and full year 2020 financial results on February 25, 2021, after market close. A live conference call and webcast will follow at 5:00 PM ET for a discussion on the financial results and business updates. Aerie focuses on ophthalmic therapies for open-angle glaucoma, with products like Rhopressa® and Rocklatan® already in the market. The company continues to explore global expansion and additional ophthalmology treatments.
Aerie Pharmaceuticals (NASDAQ: AERI) announced that the European Commission has granted marketing authorization for Roclanda (netarsudil and latanoprost) 0.02%/0.005%, aimed at reducing elevated intraocular pressure in adults with primary open-angle glaucoma or ocular hypertension. This authorization follows a positive scientific opinion from the EMA's CHMP in November 2020. Roclanda is the only fixed-dose combination that does not include a beta blocker. Aerie is preparing for pricing discussions in Germany and evaluating collaboration opportunities in Europe.
